Get the Stockscreener App
35.39
1.55%
0.54
Pre-market:
35.35
-0.04
-0.11%
Travere Therapeutics Inc stock is traded at $35.39, with a volume of 1.17M.
It is up +1.55% in the last 24 hours and up +3.69% over the past month.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
See More
Previous Close:
$34.85
Open:
$34.45
24h Volume:
1.17M
Relative Volume:
0.54
Market Cap:
$3.17B
Revenue:
$333.87M
Net Income/Loss:
$-169.00M
P/E Ratio:
-17.35
EPS:
-2.04
Net Cash Flow:
$-157.30M
1W Performance:
-2.40%
1M Performance:
+3.69%
6M Performance:
+132.52%
1Y Performance:
+82.71%
1-Day Range:
$34.45
$35.63
1-Week Range:
$33.45
$37.50
52-Week Range:
$12.91
$37.50
Travere Therapeutics Inc Stock (TVTX) Company Profile
Name
Travere Therapeutics Inc
Sector
Industry
Phone
888-969-7879
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
35.39 | 3.12B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-27-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-05-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-20-23 | Initiated | Citigroup | Neutral |
| Sep-22-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-06-23 | Resumed | Evercore ISI | Outperform |
| Jul-21-23 | Initiated | JP Morgan | Overweight |
| Jun-07-23 | Resumed | Piper Sandler | Neutral |
| May-22-23 | Initiated | TD Cowen | Outperform |
| May-05-23 | Upgrade | Bryan Garnier | Sell → Neutral |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-21-23 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-14-22 | Initiated | Stifel | Hold |
| Dec-05-22 | Initiated | Wells Fargo | Overweight |
| Sep-21-22 | Initiated | Bryan Garnier | Sell |
| Jul-14-22 | Resumed | Canaccord Genuity | Buy |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-28-22 | Initiated | H.C. Wainwright | Buy |
| May-26-21 | Downgrade | Wedbush | Outperform → Neutral |
View All
Travere Therapeutics Inc Stock (TVTX) Latest News
Capital Fund Management S.A. Acquires Shares of 101,406 Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) CFO Christopher Cline Sells 20,000 Shares - MarketBeat
Panagora Asset Management Inc. Buys 96,062 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics CFO Sells 20,000 Shares - TradingView
Loomis Sayles & Co. L P Trims Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Is Carrying A Fair Bit Of Debt - 富途牛牛
Legal & General Group Plc Boosts Stake in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewir - The National Law Review
Travere Therapeutics (TVTX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Evercore Healthcare Conference - MarketScreener
The Insider Report: The Dip Was Bought Before the Holidays - Benzinga
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Is Travere Therapeutics Inc. stock a contrarian buyJuly 2025 Fed Impact & Verified Entry Point Signals - BỘ NỘI VỤ
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Thera - The National Law Review
Travere Therapeutics, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:TVTX) 2025-11-29 - Seeking Alpha
Travere Therapeutics stock hits 52-week high at 37.12 USD By Investing.com - Investing.com Nigeria
Travere Therapeutics stock hits 52-week high at 37.12 USD - Investing.com
TVTX: HC Wainwright Reiterates Buy Rating and Maintains Price Ta - GuruFocus
HC Wainwright & Co. Reiterates Travere Therapeutics (TVTX) Buy Recommendation - Nasdaq
Travere Therapeutics Delivers Growth As FILSPARI Drives Profits - Finimize
A Look at Travere Therapeutics’s Valuation Following FDA Updates Boosting FILSPARI’s Accessibility and Growth Prospects - Sahm
How Travere Therapeutics Inc. stock reacts to bond yieldsWeekly Stock Recap & AI Driven Stock Movement Reports - BỘ NỘI VỤ
How Travere Therapeutics Inc. stock trades during market volatilityWeekly Stock Analysis & Safe Entry Trade Reports - BỘ NỘI VỤ
Travere Therapeutics: Thriving Kidney Franchise Set To Soar On January PDUFA (TVTX) - Seeking Alpha
American Kidney Fund Hosts Third Patient Access Initiative Summit to Address Barriers to Kidney Care and Propose Innovative Solutions - GlobeNewswire Inc.
How institutional buying supports Travere Therapeutics Inc. stockMarket Trend Summary & Daily Profit Maximizing Trade Tips - newser.com
Will Travere Therapeutics Inc. stock maintain dividend yieldWeekly Earnings Recap & Real-Time Chart Breakout Alerts - newser.com
Is Travere Therapeutics Inc. stock trading at a premium valuationWeekly Loss Report & AI Driven Price Predictions - newser.com
Is Travere Therapeutics Inc. stock in correction or buying zoneJuly 2025 Fed Impact & Real-Time Chart Pattern Alerts - newser.com
(TVTX) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
What makes Travere Therapeutics Inc. stock attractive to growth funds2025 Top Decliners & Expert Approved Trade Ideas - newser.com
What indicators show strength in Travere Therapeutics Inc.July 2025 Price Swings & AI Powered Market Trend Analysis - newser.com
What momentum shifts mean for Travere Therapeutics Inc.2025 Technical Overview & Safe Capital Growth Stock Tips - newser.com
Can Travere Therapeutics Inc. stock deliver strong Q4 earningsPortfolio Risk Report & Weekly Watchlist of Top Performers - newser.com
How Travere Therapeutics Inc. stock compares to industry benchmarksQuarterly Performance Summary & Weekly Breakout Stock Alerts - newser.com
Will Travere Therapeutics Inc. stock outperform international peersTrade Risk Report & Free Expert Approved Momentum Trade Ideas - newser.com
Will Positive Phase 3 FILSPARI Data in FSGS Redefine Travere Therapeutics' (TVTX) Position in Rare Kidney Disease? - sahmcapital.com
Real time scanner hits for Travere Therapeutics Inc. explainedMarket Volume Report & Weekly High Return Stock Forecasts - newser.com
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally - AOL.com
Travere Therapeutics stock hits 52-week high at 36.81 USD By Investing.com - Investing.com Canada
Travere Therapeutics Inc Stock (TVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):